Skip to main content
Fig. 5 | Journal of Translational Medicine

Fig. 5

From: Compound α-keto acid tablet supplementation alleviates chronic kidney disease progression via inhibition of the NF-kB and MAPK pathways

Fig. 5

KA supplemented with LPD might attenuate IR induced inflammation and apoptosis by inhibiting the activation of NF-κB and MAPK pathways. a Western blot analysis and histograms of NF-κB pathway: p-p65 raised dramatically in IR + Nacl group compared to the Sham group. Its targeted molecule NFATc-1 increased after IR surgery too. KA inhibited the activation of NF-κB pathway, as well as NFATc-1. b MAPK pathway (p-p38 and p-ERK). KA presented a similar effect on MAPK pathway as NF-κB pathway. A nearly 2.0-folds increase of p-p38 was detected in IR + Nacl group compared to the Sham group. Half was decreased after the usage of KA. The expression of p-ERK was also reduced in protein level in KA group after IR. Data were presented as mean ± SD. *p < 0.05 (unpaired nonparametric t-test); n = 3/group

Back to article page